{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T01:01:22Z","timestamp":1649034082866},"reference-count":41,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T00:00:00Z","timestamp":1319155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["opendentistryjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TODENTJ"],"published-print":{"date-parts":[[2011,10,21]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Objective:<\/jats:title>\n                    <jats:p>Many clinicians will not treat patients presenting with bisphosphonate-related osteonecrosis of the jaw following long-term use of bisphosphonates because of the lack of predictable outcomes. <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Materical and Methods:<\/jats:title>\n                    <jats:p>The patient presented with pain from a nonhealing lesion in the posterior maxilla following extraction of the maxillary right third molar. The lesion had not responded to any conventional dental treatment. The patient had suffered from breast cancer, and her treatment included several years of therapy with Zometa (zoledronic acid), a bisphosphonate.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The patient stopped taking Zometa and commenced rinsing with phosphate buffer\u2013stabilized 0.1% chlorine dioxide\u2013containing mouthwash. After 5 months, changes in the morphology of the lesion were noted and the soft tissue had closed over the open wound. <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Cessation of bisphosphonate therapy and usage of a phosphate buffer\u2013stabilized 0.1% chlorine dioxide\u2013containing mouthwash lessened the patient\u2019s pain and resulted in closure of the soft tissue lesion. <\/jats:p>\n                <\/jats:sec>","DOI":"10.2174\/1874210601105010163","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T13:35:57Z","timestamp":1320154557000},"page":"163-167","update-policy":"http:\/\/dx.doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Closure of an Open Wound Associated with Bisphosphonate-Related Osteonecrosis of the Jaw in a Breast Cancer Patient"],"prefix":"10.2174","volume":"5","author":[{"given":"Nafiseh","family":"Soolari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Soolari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"refR1","unstructured":"Breastcancer.org: Breast cancer, 2010 \n                    Available: http:\/\/www.breastcancer.org  \n                     [Accessed 2011];"},{"key":"refR2","unstructured":"U.S. National Library of Medicine. \n                    Genetics home reference: Breast cancer 2007 \n                    Available: http:\/\/ghr.nlm.nih.gov\/condition=breastcancer  \n                     [Accessed 2011];"},{"key":"refR3","first-page":"281","volume":"10","year":"2004","unstructured":"ESHRE Capri Workshop Group. \n                    Hormones and breast cancer \n                    Hum Reprod  \n                    2004; \n                    10\n                    (4)\n                    : 281-3.","journal-title":"Hum Reprod"},{"key":"refR4","year":"2006","unstructured":"National Cancer Institute. \n                    Results of the study of tamoxifen and raloxifene (STAR) released: osteoporosis drug raloxifene shown to be as effective as tamoxifen in preventing invasive breast cancer \n                    Available: http:\/\/www.cancer.gov\/newscenter\/pressreleases\/STA-RresultsApr172006  \n                    2006\n                     [Accessed 2011];","journal-title":"Available: http:\/\/www.cancer.gov\/newscenter\/pressreleases\/STA-RresultsApr172006"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0714.2004.00269.x","volume":"34","author":"Bagan JV","year":"2005","unstructured":"Bagan JV. \n                    Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases \n                    J Oral Pathol Med  \n                    2005; \n                    34\n                    (2)\n                    : 120-3.","journal-title":"J Oral Pathol Med"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","volume":"21","author":"Migliorati CA","year":"2003","unstructured":"Migliorati CA. \n                    Bisphosphonates and oral cavity avascular bone necrosis \n                    J Clin Oncol  \n                    2003; \n                    21\n                    (22)\n                    : 4253-.","journal-title":"J Clin Oncol"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"Ruggiero SL","year":"2004","unstructured":"Ruggiero SL. \n                    Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases \n                    J Oral Maxillofac Surg  \n                    2004; \n                    62\n                    (5)\n                    : 527-34.","journal-title":"J Oral Maxillofac Surg"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/jop.2006.2.1.7","volume":"2","author":"Ruggiero SL","year":"2006","unstructured":"Ruggiero SL. \n                    Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer \n                    J Oncol Pract  \n                    2006; \n                    2\n                    (1)\n                    : 7-14.","journal-title":"J Oncol Pract"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"Marx RE","year":"2003","unstructured":"Marx RE. \n                    Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic \n                    J Oral Maxillofac Surg  \n                    2003; \n                    61\n                    (9)\n                    : 1115-7.","journal-title":"J Oral Maxillofac Surg"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","volume":"63","author":"Marx RE","year":"2005","unstructured":"Marx RE. \n                    Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment \n                    J Oral Maxillofac Surg  \n                    2005; \n                    63\n                    (11)\n                    : 1567-75.","journal-title":"J Oral Maxillofac Surg"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","volume":"136","author":"Migliorati CA","year":"2005","unstructured":"Migliorati CA. \n                    Managing the care of patients with bisphosphonate-associated osteonecrosis: an american academy of oral medicine position paper \n                    J Am Dent Assoc  \n                    2005; \n                    136\n                    (12)\n                    : 1658-68.","journal-title":"J Am Dent Assoc"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(06)70726-4","volume":"7","author":"Migliorati CA","year":"2006","unstructured":"Migliorati CA, Siegel MA, Elting LS. \n                    Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment \n                    Lancet Oncol  \n                    2006; \n                    7\n                    (6)\n                    : 508-14.","journal-title":"Lancet Oncol"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"Woo SB","year":"2005","unstructured":"Woo SB. \n                    Osteonecrosis of the jaw and bisphosphonates \n                    N Engl J Med  \n                    2005; \n                    353\n                    (1)\n                    : 99-102.","journal-title":"N Engl J Med"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.3816\/CBC.2005.s.005","volume":"5","author":"Gralow J","year":"2005","unstructured":"Gralow J. \n                    Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer \n                    Clin Breast Cancer  \n                    2005; \n                    5\n                    (Suppl 2)\n                    : S54-62.","journal-title":"Clin Breast Cancer"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10006-006-0017-5","volume":"10","author":"Piesold JU","year":"2006","unstructured":"Piesold JU, Al-Nawas B, Gr\u00f6tz KA. \n                    Osteonecrosis of the jaws by long term therapy with bisphosphonates \n                    Mund Kiefer Gesichtschir  \n                    2006; \n                    10\n                    (5)\n                    : 287-300.","journal-title":"Mund Kiefer Gesichtschir"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","volume":"42","author":"Chen T","year":"2002","unstructured":"Chen T, Berenson J, Vescio R, et al. \n                    Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases \n                    J Clin Pharmacol  \n                    2002; \n                    42\n                    : 1228-36.","journal-title":"J Clin Pharmacol"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/01.AOG.0000173817.16040.97","volume":"106","author":"Thorpe J","year":"2005","unstructured":"Thorpe J. \n                    Alendronate (Fosamax) and risedronate (Actonel) revisited \n                    Obstet Gynecol  \n                    2005; \n                    106\n                    (2)\n                    : 402-.","journal-title":"Obstet Gynecol"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","volume":"355","author":"Bilezikian JP","year":"2006","unstructured":"Bilezikian JP. \n                    Osteonecrosis of the jaw: do bisphosphonates pose a risk? \n                    N Engl J Med  \n                    2006; \n                    355\n                    (22)\n                    : 2278-81.","journal-title":"N Engl J Med"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bone.2006.11.023","volume":"40","author":"Dannemann C","year":"2007","unstructured":"Dannemann C, Gr\u00e4tz KW, Riener MO, Zwahlen RA. \n                    Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder \n                    Bone  \n                    2007; \n                    40\n                    (4)\n                    : 828-34.","journal-title":"Bone"},{"key":"refR20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ajh.20481","volume":"81","author":"Zarychanski R","year":"2006","unstructured":"Zarychanski R. \n                    Osteonecrosis of the jaw associated with pamidronate therapy \n                    Am J Hematol  \n                    2006; \n                    81\n                    (1)\n                    : 73-5.","journal-title":"Am J Hematol"},{"key":"refR21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","volume":"62","author":"Weitzman R","year":"2007","unstructured":"Weitzman R, Sauter N, Eriksen E, et al. \n                    Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients \n                    Crit Rev Oncol Hema-tol  \n                    2007; \n                    62\n                    (2)\n                    : 148-52.","journal-title":"Crit Rev Oncol Hema-tol"},{"key":"refR22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0025-7753(06)72338-7","volume":"127","author":"Calvo-Villas JM","year":"2006","unstructured":"Calvo-Villas JM. \n                    Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid \n                    Med Clin (Barc)  \n                    2006; \n                    127\n                    (15)\n                    : 576-9.","journal-title":"Med Clin (Barc)"},{"key":"refR23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","volume":"134","author":"Zervas K","year":"2006","unstructured":"Zervas K, Verrou E, Teleioudis Z, et al. \n                    Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients \n                    Br J Haematol  \n                    2006; \n                    134\n                    (6)\n                    : 620-3.","journal-title":"Br J Haematol"},{"key":"refR24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","volume":"65","author":"Mavrokokki T","year":"2007","unstructured":"Mavrokokki T, Cheng A, Stein B, Goss A. \n                    Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia \n                    J Oral Maxillofac Surg  \n                    2007; \n                    65\n                    (3)\n                    : 415-23.","journal-title":"J Oral Maxillofac Surg"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"Bamias A","year":"2005","unstructured":"Bamias A. \n                    Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors \n                    J Clin Oncol  \n                    2005; \n                    23\n                    (34)\n                    : 8580-7.","journal-title":"J Clin Oncol"},{"key":"refR26","first-page":"44","volume":"3","author":"Rose L","year":"2007","unstructured":"Rose L, Ruggiero S, Silverstein L. \n                    When can patients who are being treated with oral and IV bisphosphonates receive periodontal, implant, and\/or oral surgical care? \n                    Inside Dent  \n                    2007; \n                    3\n                    (9)\n                    : 44-5.","journal-title":"Inside Dent"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1138\/20060228","volume":"3","author":"Somerman MJ","year":"2006","unstructured":"Somerman MJ, McCauley LK. \n                    Bisphosphonates: sacrificing the jaw to save the skeleton? \n                    IBMS BoneKey  \n                    2006; \n                    3\n                    (9)\n                    : 12-5.","journal-title":"IBMS BoneKey"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1345\/aph.1H521","volume":"41","author":"Krueger CD","year":"2007","unstructured":"Krueger CD, West PM, Sargent M, Lodolce AE, Pickard AS. \n                    Bisphosphonate-induced osteonecrosis of the jaw \n                    Ann Pharmacother  \n                    2007; \n                    41\n                    (2)\n                    : 276-84.","journal-title":"Ann Pharmacother"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.oraloncology.2005.08.001","volume":"42","author":"Bagan JV","year":"2006","unstructured":"Bagan JV, Jimenez Y, Murillo J, et al. \n                    Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. study of 20 cases \n                    Oral Oncol  \n                    2006; \n                    42\n                    (3)\n                    : 327-9.","journal-title":"Oral Oncol"},{"key":"refR30","first-page":"753","volume":"44","author":"Woo SB","year":"2006","unstructured":"Woo SB, Hellstein JW, Kalmar JR. \n                    Narrative review: bisphosphonates and osteonecrosis of the jaws \n                    Ann Intern Med  \n                    2006; \n                    44\n                    (10)\n                    : 753-61.","journal-title":"Ann Intern Med"},{"key":"refR31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/01.mlg.0000187398.51857.3c","volume":"116","author":"Farrugia MC","year":"2006","unstructured":"Farrugia MC, Summerlin DJ, Krowiak E, et al. \n                    Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates \n                    Laryngoscope  \n                    2006; \n                    116\n                    : 115-20.","journal-title":"Laryngoscope"},{"key":"refR32","first-page":"584","volume":"78","author":"Wang H","year":"2007","unstructured":"Wang H, Weber D, McCauley LK. \n                    Effect of long-term oral bisphosphonate on implant wound healing: literature review and a case report \n                    J Orofac Pain  \n                    2007; \n                    78\n                    : 584-94.","journal-title":"J Orofac Pain"},{"key":"refR33","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1210\/jc.2006-2036","volume":"92","author":"Khamaisi M","year":"2007","unstructured":"Khamaisi M, Regev E, Yarom N, et al. \n                    Possible association between diabetes and bisphosphonate-related jaw osteonecrosis \n                    J Clin Endocrinol Metab  \n                    2007; \n                    92\n                    (3)\n                    : 1172-5.","journal-title":"J Clin Endocrinol Metab"},{"key":"refR34","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","volume":"21","author":"Corso A","year":"2007","unstructured":"Corso A, Varettoni M, Zappasodi P, et al. \n                    Different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma \n                    Leukemia  \n                    2007; \n                    21\n                    (7)\n                    : 1545-8.","journal-title":"Leukemia"},{"key":"refR35","doi-asserted-by":"crossref","first-page":"971","DOI":"10.14219\/jada.archive.2007.0294","volume":"138","author":"Adornato MC","year":"2007","unstructured":"Adornato MC, Morcos I, Rozanski J. \n                    The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone re-section and autologous platelet-derived growth factors \n                    J Am Dent Assoc  \n                    2007; \n                    138\n                    (7)\n                    : 971-7.","journal-title":"J Am Dent Assoc"},{"key":"refR36","unstructured":"American Academy of Periodontology. \n                    AAP Statement on Bisphosphonates, 2010 \n                    Available: www.perio.org\/resources-products\/bisphosphonates.htm  \n                     [Accessed 20 March 2011];"},{"key":"refR37","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.14219\/jada.archive.2009.0049","volume":"140","author":"Sedghizadeh PP","year":"2009","unstructured":"Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. \n                    Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy \n                    J Am Dent Assoc  \n                    2009; \n                    140\n                    (10)\n                    : 1259-65.","journal-title":"J Am Dent Assoc"},{"key":"refR38","first-page":"67","volume":"12","author":"Grootvelt M","year":"2001","unstructured":"Grootvelt M, Silwood C, Gill D, Lynch E. \n                    Evidence for the microbicidal activity of a chlorine dioxide-containing oral rinse formulation in vivo \n                    J Clin Dent  \n                    2001; \n                    12\n                    (3)\n                    : 67-70.","journal-title":"J Clin Dent"},{"key":"refR39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6215-11-14","volume":"11","author":"Shinada K","year":"2010","unstructured":"Shinada K, Ueno M, Konishi C, et al. \n                    Effects of a mouthwash with chlorine dioxide on oral malodor and salivary bacteria: a randomized placebo-controlled 7-day trial \n                    Trials  \n                    2010; \n                    11\n                    : 14.","journal-title":"Trials"},{"key":"refR40","first-page":"7","volume":"1","author":"Soolari E","year":"2010","unstructured":"Soolari E, Soolari A, Soolari A. \n                    Phosphate buffer-stabilized 0.1% chlorine dioxide-containing mouth wash facilitate sequestration of bisphosphonate related osteonecrosis of jaw (BRONJ) lesion from a patient who presented with osteonecrosis of the jaw and a history of intravenous bisphosphonate use: case report \n                    Translation Biomed  \n                    2010; \n                    1\n                    (1)\n                    : 7.","journal-title":"Translation Biomed"},{"key":"refR41","first-page":"99","volume":"27","author":"Marder MZ","year":"2008","unstructured":"Marder MZ, Marder RW. \n                    Bisphosphonate-associated osteonecrosis experiences in a private practice \n                    Dent Today  \n                    2008; \n                    27\n                    (10)\n                    : 99-103.","journal-title":"Dent Today"}],"container-title":["The Open Dentistry Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/opendentistryjournal.com\/contents\/volumes\/V5\/TODENTJ-5-163\/TODENTJ-5-163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opendentistryjournal.com\/contents\/volumes\/V5\/TODENTJ-5-163\/TODENTJ-5-163.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opendentistryjournal.com\/contents\/volumes\/V5\/TODENTJ-5-163\/TODENTJ-5-163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T07:35:11Z","timestamp":1553499311000},"score":1,"resource":{"primary":{"URL":"https:\/\/opendentistryjournal.com\/VOLUME\/5\/PAGE\/163\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,21]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,10,21]]}},"alternative-id":["TODENTJ-5-163"],"URL":"https:\/\/doi.org\/10.2174\/1874210601105010163","relation":{},"ISSN":["1874-2106"],"issn-type":[{"value":"1874-2106","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10,21]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2011-6-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-9-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-9-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}